ArticleMedicine2022
Mechanistic insights into the use of rhubarb in diabetic kidney disease treatment using network pharmacology.
Article in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Article
- Physcion inhibition of CYP2C9, 2D6 and 3A4 in human liver microsomes.Pharmaceutical biology · 2024Article
- [Euonymus alatus delays progression of diabetic kidney disease in mice by regulating EGFR tyrosine kinase inhibitor resistance signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractIn this study, we predicted the core active compounds of rhubarb used in the treatment of diabetic kidney disease (DKD) and the related core gene targets and pathways using network pharmacological approaches.The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform was used to identify active compounds of rhubarb. PharmMapper was used to predict the gene targets of active compounds, which were subsequently provided a standard nomenclature using the UniProt database. In addition, DKD-related target genes were predicted using GeneCards, Online Mendelian Inheritance in Man, and Therapeutic Target Database. The genes that were targeted both by rhubarb active compounds and implicated in DKD (hereafter referred to as overlapping target genes) were identified using Venny 2.1. A drug-target-disease network diagram was obtained using Cytoscape and a protein-protein interaction network diagram was constructed using the STRING database. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses of overlapping target proteins were performed using the Database for Annotation, Visualization and Integrated Discovery Bioinformatics Resources 6.8.Eighteen core active compounds of rhubarb were extracted, and 136 target genes of rhubarb were identified. Some of the active compounds revealed by the network pharmacological analysis were catechin, aloe-emodin, rhein, and emodin; certain core target proteins suggested by the protein-protein interaction network analysis were AKT1, PIK3R1, and SRC. The overlapping target genes were primarily involved in apoptosis and proteolysis, with the PI3K/Akt signaling pathway identified as significantly enriched.Network pharmacological strategies were used to identify core active compounds of rhubarb and their related pathways. We believe that our study will provide potential and effective novel targets to identify active compounds of rhubarb for treating DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.